 Connection
Gregory Schwartz to Percutaneous Coronary Intervention
This is a "connection" page, showing publications Gregory Schwartz has written about Percutaneous Coronary Intervention.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.139 |
|
|
|
-
Ray KK, Nicholls SJ, Ginsberg HD, Johansson JO, Kalantar-Zadeh K, Kulikowski E, Toth PP, Wong N, Cummings JL, Sweeney M, Schwartz GG. Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial. Am Heart J. 2019 11; 217:72-83.
Score: 0.114
-
Morici N, Savonitto S, Ponticelli C, Schrieks IC, Nozza A, Cosentino F, St?hli BE, Perrone Filardi P, Schwartz GG, Mellbin L, Lincoff AM, Tardif JC, Grobbee DE. Post-Discharge Worsening Renal Function in Patients with Type 2 Diabetes and Recent Acute?Coronary Syndrome. Am J Med. 2017 09; 130(9):1068-1075.
Score: 0.024
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|